This page has only limited features, please log in for full access.
Cardiovascular diseases (CVDs) are considered as a major cause of death worldwide. Therefore, identifying and developing therapeutic strategies to treat and reduce the prevalence of CVDs is a major medical challenge. Several drugs used for the treatment of CVDs, such as captopril, emerged from natural products, namely snake venoms. These venoms are complex mixtures of bioactive molecules, which, among other physiological networks, target the cardiovascular system, leading to them being considered in the development and design of new drugs. In this review, we describe some snake venom molecules targeting the cardiovascular system such as phospholipase A2 (PLA2), natriuretic peptides (NPs), bradykinin-potentiating peptides (BPPs), cysteine-rich secretory proteins (CRISPs), disintegrins, fibrinolytic enzymes, and three-finger toxins (3FTXs). In addition, their molecular targets, and mechanisms of action—vasorelaxation, inhibition of platelet aggregation, cardioprotective activities—are discussed. The dissection of their biological effects at the molecular scale give insights for the development of future snake venom-derived drugs.
Jacinthe Frangieh; Mohamad Rima; Ziad Fajloun; Daniel Henrion; Jean-Marc Sabatier; Christian Legros; César Mattei. Snake Venom Components: Tools and Cures to Target Cardiovascular Diseases. Molecules 2021, 26, 2223 .
AMA StyleJacinthe Frangieh, Mohamad Rima, Ziad Fajloun, Daniel Henrion, Jean-Marc Sabatier, Christian Legros, César Mattei. Snake Venom Components: Tools and Cures to Target Cardiovascular Diseases. Molecules. 2021; 26 (8):2223.
Chicago/Turabian StyleJacinthe Frangieh; Mohamad Rima; Ziad Fajloun; Daniel Henrion; Jean-Marc Sabatier; Christian Legros; César Mattei. 2021. "Snake Venom Components: Tools and Cures to Target Cardiovascular Diseases." Molecules 26, no. 8: 2223.
Apitherapy is an alternate therapy that relies on the usage of honeybee products, most importantly bee venom for the treatment of many human diseases. The venom can be introduced into the human body by manual injection or by direct bee stings. Bee venom contains several active molecules such as peptides and enzymes that have advantageous potential in treating inflammation and central nervous system diseases, such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis. Moreover, bee venom has shown promising benefits against different types of cancer as well as anti-viral activity, even against the challenging human immunodeficiency virus (HIV). Many studies described biological activities of bee venom components and launched preclinical trials to improve the potential use of apitoxin and its constituents as the next generation of drugs. The aim of this review is to summarize the main compounds of bee venom, their primary biological properties, mechanisms of action, and their therapeutic values in alternative therapy strategies.
Rim Wehbe; Jacinthe Frangieh; Mohamad Rima; Dany El Obeid; Jean-Marc Sabatier; Ziad Fajloun. Bee Venom: Overview of Main Compounds and Bioactivities for Therapeutic Interests. Molecules 2019, 24, 2997 .
AMA StyleRim Wehbe, Jacinthe Frangieh, Mohamad Rima, Dany El Obeid, Jean-Marc Sabatier, Ziad Fajloun. Bee Venom: Overview of Main Compounds and Bioactivities for Therapeutic Interests. Molecules. 2019; 24 (16):2997.
Chicago/Turabian StyleRim Wehbe; Jacinthe Frangieh; Mohamad Rima; Dany El Obeid; Jean-Marc Sabatier; Ziad Fajloun. 2019. "Bee Venom: Overview of Main Compounds and Bioactivities for Therapeutic Interests." Molecules 24, no. 16: 2997.
Bee venom is a mixture of several components with proven therapeutic benefits, among which are anti-inflammatory, analgesic, and various cardiovascular conditions. In this work, we analyzed for the first time the proteomic content and biological properties of the crude venom from Apis mellifera syriaca, a honeybee from the Middle East region. Using high-performance liquid chromatography-tandem mass spectrometry, we evidence the venom contains phospholipase A2, hyaluronidase, mast cell-degranulating peptide, adolapin, apamin, and melittin. The latter was purified by solid phase extraction method (SPE) and tested in parallel with crude venom for biological activities. Precisely, crude venom-but not melittin-exhibited antibacterial activity against Staphylococcus aureus and Pseudomonas aeruginosa strains. Alongside, hemolytic activity was observed in human blood subjected to the venom at high doses. A. mellifera syriaca venom displayed antioxidant activities, and not surprisingly, PLA2 catalytic activity. Eventually, the venom proved to exert antiproliferative effects against MCF-7 and 3T3 cancer cells lines. This first report of a new bee venom opens new avenues for therapeutic uses of bee venoms.
Jacinthe Frangieh; Yahya Salma; Katia Haddad; Cesar Mattei; Christian Legros; Ziad Fajloun; Dany El Obeid. First Characterization of The Venom from Apis mellifera syriaca, A Honeybee from The Middle East Region. Toxins 2019, 11, 191 .
AMA StyleJacinthe Frangieh, Yahya Salma, Katia Haddad, Cesar Mattei, Christian Legros, Ziad Fajloun, Dany El Obeid. First Characterization of The Venom from Apis mellifera syriaca, A Honeybee from The Middle East Region. Toxins. 2019; 11 (4):191.
Chicago/Turabian StyleJacinthe Frangieh; Yahya Salma; Katia Haddad; Cesar Mattei; Christian Legros; Ziad Fajloun; Dany El Obeid. 2019. "First Characterization of The Venom from Apis mellifera syriaca, A Honeybee from The Middle East Region." Toxins 11, no. 4: 191.